Back FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors 06/05/2023 Read more https://www.businesswire.com/news/home/20230604005037/en/FogPharma-Announces-First-Patient-Dosed-in-Phase-12-Clinical-Trial-of-First-in-class-TCF-blocking-%CE%B2-catenin-Inhibitor-FOG-001-in-Advanced-Solid-Tumors
